A Phase 1, Two-Part Study to Assess the Safety and Pharmacokinetics of Tablet and Capsule Formulations of HU6 in Obese Subjects
Latest Information Update: 22 Mar 2023
At a glance
- Drugs HU 6 (Primary)
- Indications Heart failure; Hypertriglyceridaemia; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Rivus Pharmaceuticals
Most Recent Events
- 15 Mar 2023 Status changed from not yet recruiting to completed.
- 30 Jun 2022 New trial record